FY2025 EPS Estimates for GSK plc Lifted by Zacks Research (NYSE:GSK)

GSK plc (NYSE:GSK) – Zacks Research increased their FY2025 earnings per share estimates for shares of GSK in a research report issued on Tuesday, June 25th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings per share of $4.47 for the year, up from their previous estimate of $4.41. The consensus estimate for GSK’s current full-year earnings is $4.11 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $1.01 EPS and FY2026 earnings at $4.91 EPS.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, beating the consensus estimate of $0.94 by $0.15. The company had revenue of $9.34 billion during the quarter, compared to the consensus estimate of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%.

Other analysts also recently issued reports about the company. Citigroup upgraded GSK to a “strong-buy” rating in a research note on Monday. The Goldman Sachs Group initiated coverage on GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price for the company. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Berenberg Bank upgraded GSK to a “strong-buy” rating in a research note on Thursday, June 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

GSK Stock Performance

Shares of GSK opened at $38.66 on Thursday. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. The stock has a 50-day moving average of $42.55 and a 200-day moving average of $41.17. The company has a market cap of $80.12 billion, a PE ratio of 13.97, a P/E/G ratio of 1.22 and a beta of 0.66. GSK has a one year low of $33.67 and a one year high of $45.92.

Hedge Funds Weigh In On GSK

Hedge funds have recently modified their holdings of the company. JTC Employer Solutions Trustee Ltd raised its holdings in shares of GSK by 71.3% in the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock worth $909,063,000 after purchasing an additional 8,800,822 shares during the period. Hsbc Holdings PLC bought a new stake in shares of GSK in the 4th quarter worth approximately $92,281,000. Armistice Capital LLC raised its holdings in shares of GSK by 670.5% in the 4th quarter. Armistice Capital LLC now owns 2,196,000 shares of the pharmaceutical company’s stock worth $81,384,000 after purchasing an additional 1,911,000 shares during the period. Mondrian Investment Partners LTD raised its holdings in GSK by 37.8% during the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after acquiring an additional 1,512,442 shares during the period. Finally, Fisher Asset Management LLC lifted its position in shares of GSK by 10.8% during the fourth quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock worth $558,330,000 after acquiring an additional 1,465,165 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. The ex-dividend date is Thursday, May 16th. This represents a $1.50 annualized dividend and a dividend yield of 3.89%. This is a boost from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio (DPR) is currently 53.26%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.